Evolving hepatitis C pipeline offers hope to patients
Evolving hepatitis C pipeline offers hope to patientsCost burden prompts payers to consider appropriate utilization
FDA approves changes to hep C drug label to include new warningsFDA has approved changes to the hepatitis C antiviral simeprevir (Olysio, Janssen) label to include new warnings about serious symptomatic bradycardia—slowing of the heart rate—when co-administered with antiarrhythmic drug amiodarone and antiviral sofosbuvir (Solvaldi, Gilead).
FDA approves Viekira Pak to treat hepatitis CFDA has approved ombitasvir, paritaprevir and ritonavir tablets co-packaged with dasabuvir tablets (Viekira Pak, AbbVie) to treat patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those with a type of advanced liver disease called cirrhosis.
Olysio indication expanded for combo use with Sovaldi in hepatitis CFDA has approved simeprevir (Olysio, Janssen) in combination with sofosbuvir (Sovaldi, Gilead) as an oral, interferon- and ribavirin-free treatment option for genotype 1 chronic hepatitis infection in adults.
FDA drug approvals-November 2014FDA drug approvals, fast-track designations
Treating hepatitis C means expanded role for primary careWhat screening recommendations and the arrival of new—but expensive—treatments means for primary care practices
New treatment combo for hep C virus infection, genotype 1Once-daily simeprevir should be used in combination with peginterferon alpha and ribavirin. It is not a monotherapy.
The evolving role of pharmacists in treatment of Hepatitis CBy maintaining a strong knowledge base about HCV infection and management, pharmacists can be a resource to providers and patients alike.
AMCP: Optimize therapeutic decision making for hepatitis C drug treatmentsTo help manage costs, the panel noted that managed care organizations could move coverage of the new orals into the pharmacy benefit
BLOG: Hepatitis C and an expanding specialty pharmacy market basket of drugs